Jun
2026
Shanghai New International Expo Center
Visit us
stand E1F22, Pharma Ingredients

Ministry of Health, The United Republic of Tanzania

Exhibitor at CPHI & PMEC China 2026
About Us

Tanzania's Pharmaceutical Investment Acceleration Taskforce (PIAT), the Government's whole-of-government mechanism for fast-tracking strategic pharmaceutical investment, has arrived in Shanghai for CPHI China 2026, held at the Shanghai New International Expo Center from 16 to 18 June. The delegation will engage directly with international manufacturers, active pharmaceutical ingredient (API) producers, and contract manufacturing organisations to present Tanzania's case as Africa's next pharmaceutical manufacturing hub.

Read more Show less
Sales Markets
Show more Show less
Categories
more categories Show less
  • Country/Region:
    Tanzania, United Republic of
  • Founded:
    1961
  • On CPHI since:
    2026
  • Certificates:
    1
  • Employees:
    5000+
Company types
Other
Primary activities
Other
View company profile
Contact info
  • +255760555506
  • Website
  • Ministry of Health, The United Republic of Tanzania, Wizara ya Afya, P.O. Box 743, 255, Dar-es-Salaam, Tanzania, Tanzania, United Republic of
Show contact info Hide contact info
Event information
CPHI & PMEC China 2026
  • 16 Jun 2026 - 18 Jun 2026
  • Shanghai New International Expo Center
  • Visit us at stand E1F22, Pharma Ingredients

Products Featured at CPHI & PMEC China 2026

  • Tier 1 — Essential Medicines Manufacturing

    Product Tier 1 — Essential Medicines Manufacturing

    Opportunity — substitute 20-40% of the USD 800M-1B annual import bill. Target WHO-GMP-compliant production of human medicines for infectious and non-infectious diseases including anti-TB, anti-cancer, ARVs, first-line anti-malarials.▸Market assurance — 15% MSD procurement preference; framework agreements; ...
  • Tier 2 — API & Excipients Manufacturing

    Product Tier 2 — API & Excipients Manufacturing

    Tier 2 — API & Excipients Manufacturing▸Opportunity — zero API manufacturing capacity in the entire EAC region; 100% of APIs currently imported.▸Strategic priority — designated by TMDA and PIAT as a medium-to-long-term focus; highest policy priority.▸Investment range — USD 50-200M for scaled API produc...
  • Tier 4 — Small Volume Parenterals

    Product Tier 4 — Small Volume Parenterals

    Tier 4 — Small Volume Parenterals▸Opportunity — no ampoules or vials manufacturing in Tanzania. Huge demand across hospitals, immunisation, emergency medicine.▸Investment range — USD 20-60M for a compliant facility.